Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 7/20 | 0.39 |
| ▸ | BACE1 | P56817 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311003 | 0.90 | DRD2 (0.34) | CTSDBACE1CYP3A4DRD2 | |
| SCHEMBL310161 | 0.88 | CTSD (0.42) | CTSDBACE1CYP3A4 | |
| SCHEMBL309772 | 0.87 | CTSD (0.40) | CTSDBACE1CYP3A4 | |
| SCHEMBL3653594 | 0.87 | CTSD (0.38) | CTSDBACE1CYP3A4CNR2 | |
| SCHEMBL3653039 | 0.87 | CTSD (0.38) | CTSDBACE1CYP3A4CNR2 | |
| SCHEMBL309208 | 0.84 | BACE1 (0.42) | CTSDBACE1CYP3A4 | |
| SCHEMBL3646307 | 0.83 | DRD2 (0.31) | DRD2 | |
| SCHEMBL3650137 | 0.80 | DRD2 (0.34) | CTSDBACE1DRD2 | |
| SCHEMBL3652166 | 0.80 | DRD2 (0.34) | CTSDBACE1DRD2 | |
| SCHEMBL3217314 | 0.80 | DRD2 (0.34) | CTSDBACE1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| EP-2303857-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2190833-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis Ag (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2010003976-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | CTSD 38/4885BACE1 2/4885CYP3A4 978/4885 |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | CTSD 33/4885BACE1 2/4885CYP3A4 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.